STUTTGART, Germany I October 22, 2013 I A new report released by La Merie Publishing analyzes the opportunities arising from the use of the T-cell receptor (TCR) in recombinant protein and antibody products as well as in T-cell therapy. The report entitled „The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry“ describes the current state-of-the art of TCR technologies including the monoclonal TCR (mTCR) and single-chain TCR (scTCR) in immunoglobulin and immunocytokine fusion proteins as well as in cytotoxic T-lymphocytes. The unique feature of the T-cell receptor is its ability to target intracellular protein derived peptides presented in the context of the HLA system. This opens up a whole new avenue for targeting in cancer and viral diseases by rendering intracellular antigens so far undruggable to targets accessible for antibodies, proteins and cellular therapies. This approach is becoming validated no only by the first commercial agreements between Big Pharma/Biotech and TCR technology providers, but also by clinical studies with the first TCR-based therapeutics in development.
The report can be found at http://pipelinereview.com/index.php/therapeuticarea/oncology/the-engineered-t-cell-receptor-in-fusion-proteins-antibodies-cells-emerging-opportunities-for-the-biopharmaceutical-industry-detail. This investigation summarizes current activities in the TCR field presents upcoming commercial opportunities for the pharmaceutical and biotechnology industry. As a rather new field of reserach and development in the pharma industry, there are still untapped areas for new entrants regarding platform technologies and products for development.
About La Merie Publising
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish reports, offer R&D database access, and provide consulting services in pharmacology and biotechnology. Our products and subscription services are commercialized via our associated biotech portal www.PipelineReview.com To read more about La Merie Publising, plrase visit our website www.lamerie.com